A prophylactic hepatitis B vaccine with a novel adjuvant system.
about
Toll-like receptors: the swiss army knife of immunity and vaccine developmentAdjuvants: Classification, Modus Operandi, and LicensingImmune Adjuvant Effect of Molecularly-defined Toll-Like Receptor LigandsEnhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.Lipid tucaresol as an adjuvant for methamphetamine vaccine development.Recent progress in herpes simplex virus immunobiology and vaccine researchToll-like receptor agonists: are they good adjuvants?Immunization with the recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis.TLR-based immune adjuvants.Inefficient TLR4/MD-2 heterotetramerization by monophosphoryl lipid AAn overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccinesSingle and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal modelsNext Generation Cancer Protection: The Bivalent HPV Vaccine for FemalesTaking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents.Improving hepatitis B vaccine efficacy in end-stage renal diseases patients and role of adjuvantsNew hepatitis B vaccine formulated with an improved adjuvant system.A review of multiple approaches towards an improved hepatitis B vaccine.Advances in effective vaccine development against hepatitis B: focus on mucosal vaccine delivery strategies.Effect of monophosphoryl lipid A on antibody response to diphtheria toxin and its subunits.Nanostructured SBA-15 silica as an adjuvant in immunizations with hepatitis B vaccine.Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus.Novel strategies in vaccine design: can nanocapsules help prevent and treat hepatitis B?Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro.
P2860
Q26746644-F37EB899-1C00-43C1-BF0D-11EEE175E27AQ26747586-870DE50E-525F-45B5-A8D4-75E9679FBBB3Q28972540-49F866BA-F4E7-407B-AC4D-25C04B540139Q30730983-3EEB035F-49DC-4B71-B1DB-BA7A1B80BA66Q33662748-74940B33-C7DE-4CD6-B68A-2F2F42AE3B75Q33963713-7947E917-3281-416E-932F-652DB9FBC683Q34067537-355F9A5D-ABFD-4ADA-B81E-3BD3FAB21526Q34127607-7D21691D-61B1-43D9-9638-D1B2B18E0E26Q34400322-4665CCC7-1BEA-41CD-960B-F7A74A9D514CQ34701875-8E356171-D44F-4BA3-84BF-8DEE1E2251A9Q35100779-BE25F237-C238-4A55-B404-06476B8DF0BBQ35271194-0FAE2E6F-1D68-4D87-AEC8-1F617F239267Q35550810-6E5171B2-37DB-4D3D-AED0-60C2470D5065Q35842681-5B243E9E-AC40-4E43-81BE-628694E3F860Q36279736-ED57A61F-B589-489E-9274-989BA16A5C8DQ36780117-2095AD0D-8619-408F-B08D-9164708EAA9EQ37481243-B5F2E4C5-59B7-4991-A3F8-DA0BFF8CD949Q38027857-5778FDAA-96DB-4945-9E57-A0EEF4F239FBQ40426143-EE0FC288-7028-4198-A6AF-EDFF1D83C107Q44021004-D4F59EC4-B208-4C10-830D-B69A497C821FQ45325639-1660CF7D-A20C-4CF1-AC87-ED601AEB85A4Q53285668-A2E3ADAB-32C3-4A90-9CB5-E70B8118F4B5Q53749471-7D7841A0-EAC2-4D37-B9C4-313625B83DFC
P2860
A prophylactic hepatitis B vaccine with a novel adjuvant system.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A prophylactic hepatitis B vaccine with a novel adjuvant system.
@ast
A prophylactic hepatitis B vaccine with a novel adjuvant system.
@en
A prophylactic hepatitis B vaccine with a novel adjuvant system.
@nl
type
label
A prophylactic hepatitis B vaccine with a novel adjuvant system.
@ast
A prophylactic hepatitis B vaccine with a novel adjuvant system.
@en
A prophylactic hepatitis B vaccine with a novel adjuvant system.
@nl
prefLabel
A prophylactic hepatitis B vaccine with a novel adjuvant system.
@ast
A prophylactic hepatitis B vaccine with a novel adjuvant system.
@en
A prophylactic hepatitis B vaccine with a novel adjuvant system.
@nl
P2093
P1433
P1476
A prophylactic hepatitis B vaccine with a novel adjuvant system.
@en
P2093
De Clercq N
Tornieporth N
P304
P356
10.1016/S0264-410X(00)00462-X
P407
P577
2001-03-01T00:00:00Z